Eton Pharmaceuticals (NASDAQ:ETON) Given New $30.00 Price Target at Craig Hallum

Eton Pharmaceuticals (NASDAQ:ETON) had its price target raised by Craig Hallum from $29.00 to $30.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other brokerages have also commented on ETON. Wall Street Zen lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. HC Wainwright raised their target price on Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Monday. Zacks Research raised Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $31.00.

Eton Pharmaceuticals Stock Performance

NASDAQ:ETON opened at $17.45 on Tuesday. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19. The firm’s fifty day simple moving average is $16.22 and its 200 day simple moving average is $17.24. The stock has a market cap of $468.01 million, a P/E ratio of -69.80 and a beta of 1.19. Eton Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $23.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. State of Alaska Department of Revenue purchased a new stake in shares of Eton Pharmaceuticals during the third quarter valued at approximately $30,000. Ameritas Investment Partners Inc. bought a new position in Eton Pharmaceuticals in the 2nd quarter valued at approximately $37,000. Quarry LP purchased a new stake in Eton Pharmaceuticals during the 3rd quarter valued at $37,000. Legal & General Group Plc bought a new stake in shares of Eton Pharmaceuticals in the 2nd quarter worth $41,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Eton Pharmaceuticals in the fourth quarter worth $44,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: In‑license and upcoming commercial launch of HEMANGEOL®: Eton acquired U.S. commercialization rights to HEMANGEOL (the only FDA‑approved systemic therapy for infantile hemangioma) and will begin U.S. commercialization on May 1, 2026. Management says the deal is expected to be accretive to 2026 earnings and will be supported by Eton’s Eton Cares patient program (including a $0 co‑pay initiative). Read More.
• Positive Sentiment: Analyst upgrades/price target increases: Two boutique research firms raised targets and maintain Buy ratings — HC Wainwright moved its target to $37 and Craig Hallum to $30, both implying large upside versus current levels. Analyst optimism likely supported earlier buying ahead of the launch. Read More.
• Positive Sentiment: Market reaction to the acquisition: Coverage and headlines from MarketWatch and BayStreet reported shares rising on the HEMANGEOL commercialization news, consistent with the accretion story and product leverage to 2026 revenue. Read More.
• Neutral Sentiment: Upcoming earnings date announced: Eton will report Q4 and full‑year 2025 results on March 19, 2026 (conference call at 4:30 p.m. ET). That event can amplify volatility as investors reassess revenue and margin drivers tied to recent product additions. Read More.
• Neutral Sentiment: Short‑interest data appears anomalous: Recent short‑interest entries show zero shares/NaN changes and 0.0 days‑to‑cover — likely a reporting/data issue rather than a market signal. Investors should treat short‑interest readings with caution until corrected. (Internal data entries)
• Negative Sentiment: Safety profile and commercialization execution risks: HEMANGEOL carries serious safety warnings (hypoglycemia, bradycardia, breathing problems, stroke risk in certain patients). Successful commercialization and physician/patient adoption are not guaranteed and could limit uptake or invite additional scrutiny. Read More.
• Negative Sentiment: Profitability and balance‑sheet context: Eton remains unprofitable (negative P/E) and will fund the HEMANGEOL deal from cash on hand; investors should watch upcoming results for margin impact, cash burn, and whether sales trajectories meet the accretion assumptions analysts used in raising targets.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.